In vivo treatment with CDK4/6 inhibitors increased PD-L1 levels of tumor cells and sensitized ICBs, resulting in tumor regression in mice receiving combined palbociclib and anti-PD-1. The gene discussed is CDK4; the disease is neoplasm.